Resection versus radiosurgery for patients with brain metastases

Future Oncology

Volumn 3, Issue 1, 2007, Pages 95-102

  Siker, Malika L ^a   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Brain metastases; Efaproxaril; Gefitinib; Motexafin gadolinium; MPC 6827; Neurosurgery; Radiosurgery; Radiotherapy; Temozolomide; Whole brain radiation therapy

Indexed keywords

BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; HUMAN; NEUROIMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIOSURGERY; REVIEW; STEREOTAXIC SURGERY; SURVIVAL RATE; TUMOR VASCULARIZATION;

ADULT; BRAIN NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; RADIOSURGERY;

EID: 33847072268     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.1.95     Document Type: Review

References (44)

1. Patchell RA: The management of brain metastases. Cancer Treat. Rev. 29, 533-540 (2003).
2. Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J. Neurooncol. 44, 275-281 (1999).
3. Gaspar L, Scott C, Rotman M et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol Biol. Phys. 37, 745-751 (1997).
4. Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47, 1001-1006 (2000).
5. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys. 43, 795-803 (1999).
6. Patchell RA, Tibbs PA, Walsh JW et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500 (1990).
7. Noordijk EM, Vecht CJ, Haaxma-Reiche H et al.: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 29, 711-717 (1994).
8. Andrews DW, Scott CB, Sperduto PW et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672 (2004).
9. Mintz AH, Kestle J, Rathbone MP et al.: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78, 1470-1476 (1996).
10. Bindal RK, Sawaya R, Leavens ME, Lee JJ: Surgical treatment of multiple brain metastases. J. Neurosurg. 79, 210-216 (1993).
11. Patchell RA, Tibbs PA, Regine WF et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489 (1998).
12. Shaw E, Scott C, Souhami L et al.: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 47, 291-298 (2000).
13. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45, 427-434 (1999).
14. Chougule PB, Burton-Williams M, Saris S et al.: Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy, or both. Int. J. Radiat. Oncol. Biol. Phys. 48, 114 (2000).
15. Sanghavi SN, Miranpuri SS, Chappell R et al.: Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int. J. Radiat. Oncol. Biol. Phys. 51, 426-434 (2001).
16. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD: Stereotactic radiosurgery for four or more intracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 64, 898-903 (2006).
17. Sneed PK, Suh JH, Goetsch SJ et al.: A multi-institutional review of radiosurgery alone vs radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 53, 519-526 (2002).
18. Aoyama H, Shirato H, Tago M et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491 (2006).
19. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N: Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat. Rev. 31, 256-273 (2005).
20. Stafinski T, Jhangri GS, Yan E, Menon D: Effectiveness of stereotactic radiosurgery alone or in combination with whole brain radiotherapy compared to conventional surgery and/or whole brain radiotherapy for the treatment of one or more brain metastases: a systematic review and meta-analysis. Cancer Treat. Rev. 32, 203-213 (2006).
21. Renschler MF, Mehta MP, Donald DM, Fondrie P, Phan S-C, Whitten TG: Treatment intent for brain metastases: surveys of medical and radiation oncologists indicate that maintaining neurologic and neurocognitive function is more important that prolonging survival. Proc. Am. Soc. Clin. Oncol. 22, 552 (2003).
22. Schulz T, Puccini S, Schneider JP, Kahn T: Interventional and intraoperative MR: review and update of techniques and clinical experience. Eur. Radiol. 14, 2212-2227 (2004).
23. Sosna J, Barth MM, Kruskal JB, Kane RA: Intraoperative sonography for neurosurgery. J. Ultrasound Med. 24, 1671-1682 (2005).
24. Bernstein M: Outpatient craniotomy for brain tumor: a pilot feasibility study in 46 patients. Can. J. Neurol. Sci. 28, 120-124 (2001).
25. Seung SK, Sneed PK, McDermott MW et al.: Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J. Sci. Am. 4, 103-109 (1998).
26. Hedde JP, Ko Y, Metzler U et al.: A Phase I/II trial of topotecan and radiation therapy for CNS-metastases of patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 22, 111 (2003).
27. Korfel A, Oehm C, von Pawel J et al.: Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre Phase II study. Eur. J. Cancer 38, 1724-1729 (2002).
28. Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL: A randomised Phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46, 107-111 (2004).
29. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide fbr glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
30. Abrey LE, Olson JD, Raizer JJ et al.: A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol. 53, 259-265 (2001).
31. Christodoulou C, Bafaloukos D, Kosmidis P et al.: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol. 12, 249-254 (2001).
32. Agarwala SS, Kirkwood JM, Gore M et al.: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol. 22, 2101-2107 (2004).
33. Dziadziuszko R, Ardizzoni A. Postmus PE et al: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. A Phase II study of the EORTC Lung Cancer Group (08965). Eur. J. Cancer 39, 1271-1276 (2003).
34. Antonadou D, Paraskevaidis M, Sarris G et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20, 3644-3650 (2002).
35. Antonadou D, Coliarakis N, Paraskevaidis M et al.: Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 54, 93 (2002).
36. Cortes J, Rodriguez J, Aramendia JM et al.: Front-line paclitaxel/ cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64, 28-35 (2003).
37. Bernardo G, Cuzzoni Q, Strada MR et al.: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a Phase II study. Cancer Invest. 20, 293-302 (2002).
38. Robinet G, Thomas P, Brecon JL, et al.: Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann. Oncol. 12, 59-67 (2001).
39. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol. 15, 1042-1047 (2004).
40. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP: Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47, 129-138 (2005).
41. Mehra MP, Rodrigus P, Terhaard CH et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21, 2529-2536 (2003).
42. Mehta MP, Carrie C, Mahe MA et al.: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a randomized Phase 3 trial. Int. J. Radiat. Oncol. Biol. Phys. 66, S23 (2006).
43. Shaw E, Scott C, Suh J et al.: RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21, 2364-2371 (2003).
44. 2), with or without RSR13 (efaproxiral) in patients with brain metastases: results of the randomized REACH (RT-009) study. Proc. Am. Soc. Clin. Oncol. 22, 1534 (2004).